9754 Results for "

double

" in MedChemExpress (MCE) Product Catalog:
Products (9754)

9754 Results for "double" in MCE Product Catalog:

Cat. No.: HY-141613
CAS No.: 90693-88-2
Purity:  ≥98.0%
Synonyms: DOPS-NA
Target:  

Liposome

Research Areas:  

Others

1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium (DOPS-NA) is a ubstitute for Phosphoserine/phosphatidylserine. 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium can be used together with DOPC and DOPE in lipid mixtures for the synthesis of liposomes. 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium can self-assemble into single-layer or double-layer membrane structures, similar to cell membranes, and possesses high membrane fluidity and flexibility. 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine is widely applied in membrane biology, cell membrane research, lipid preparation, and drug delivery systems .
loading...
    loading...
Cat. No.: HY-153605
CAS No.: 2222930-49-4
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-77 (Compound 4a) is a selective EGFR T790M/L858R inhibitor, with an IC50 of 0.101 μM against EGFR T790M/L858R, 0.477 μM against EGFR L858R, and 1.771 μM against wild-type EGFR. EGFR-IN-77 exerts selective antiproliferative effects on EGFR T790M/L858R non-small cell lung cancer. EGFR-IN-77 can be used for the research of EGFR L858R/T790M double-mutant non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-159821
CAS No.: 2830607-59-3
Synonyms: CK-4021586; CK-586
Target:  

Myosin

Research Areas:  

Cardiovascular Disease

Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
loading...
    loading...
Cat. No.: HY-164496
CAS No.: 1161826-19-2
Target:  

DNA/RNA Synthesis

Research Areas:  

Neurological Disease Cancer

KL-50 is an orally active N3-(2-fluoroethyl) imidazotetrazine DNA alkylating agent with selectivity for MGMT-deficient cells. KL-50 introduces a 2-fluoroethyl group at the O6 position of guanine, forming O6-(2-fluoroethyl) guanine (O6FEtG) lesions and further generating DNA interstrand crosslinks (ICLs). KL-50 induces DNA double-strand breaks, activates ATR-CHK1 and ATM-CHK2 DNA damage responses, and causes cell cycle arrest and micronucleus formation. KL-50 can be used for glioblastoma and DNA damage response research .
loading...
    loading...
Cat. No.: HY-174499
Target:  

mRNA

Research Areas:  

Others

Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
loading...
    loading...
Cat. No.: HY-175491
Research Areas:  

Infection

HIV-1-IN-85 is an orally active HIV-1 inhibitor (IC50 = 72 nM). HIV-1-IN-85 exhibits strong inhibitory activity against wild-type (WT) HIV-1 and NNRTI-resistant single mutant strains (L100I, K103N, Y181C, Y188L, E138K) and moderate efficacy against double mutant strains (F227L+V106A, RES056). HIV-1-IN-85 shows good in vivo safety in ICR mice. HIV-1-IN-85 can be used for the study of HIV-1 infection .
loading...
    loading...
Cat. No.: HY-175645
CAS No.: 2994637-53-3
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .
loading...
    loading...
Cat. No.: HY-181542
Research Areas:  

Cancer

SG-55 is a selective, noncompetitive and orally active AKR1C3 inhibitor with an IC50 of 5 nM and a Ki of 10 nM. SG-55 shows >2000-fold selectivity for AKR1C3 over AKR1C1, AKR1C2, and AKR1C4 (> 10 μM). SG-55 increases the ratio of reduced/oxidized nicotinamide adenine dinucleotide phosphate (NADPH/NADP +), decreases the ratio of reduced/oxidized glutathione (GSH/GSSG), and induces DNA double-strand breaks. SG-55 can overcome Osimertinib (HY-15772) resistance mediated by EGFR C797S triple mutation in non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-181967
Research Areas:  

Cancer

PROTAC PARP1 degrader-5 is a PARP1 PROTAC degrader with a DC50 of 0.12 μM. PROTAC PARP1 degrader-5 hijacks the ubiquitin-proteasome system via catalytic ternary complex formation to drive sustained PARP1 degradation. PROTAC PARP1 degrader-5 induces DNA damage, drives marginal cytosolic double-stranded DNA accumulation in tumor cells, and up-regulates PD-L1 surface expression in tumor cells. PROTAC PARP1 degrader-5 shows tumor growth inhibition activity in murine melanoma models when encapsulated in lipid nanoparticles. PROTAC PARP1 degrader-5 can be used for the research of cancer, such as melanoma .
loading...
    loading...
Cat. No.: HY-183488
CAS No.: 1207092-73-6
Synonyms: RRRRRRRRRCCLGIPEQEY
Target:  

Apoptosis PARP

Research Areas:  

Cancer

R9-caPep (RRRRRRRRRCCLGIPEQEY) is a cell-penetrating peptide derived from proliferating cell nuclear antigen (PCNA). R9-caPep selectively blocks the interactions between PCNA and FEN1, as well as between PCNA and LIGI, while preserving the binding of POLD3 to PCNA. R9-caPep interferes with DNA synthesis and homologous recombination-mediated double-strand DNA break repair, inducing S-phase arrest, DNA damage accumulation, and apoptosis. R9-caPep inhibits the growth of tumor volume and weight of neuroblastoma in nude mice . R9-caPep can be used in research related to neuroblastoma and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-187221
Research Areas:  

Infection

Anti-SARS-CoV-2 agent prodrug-1 is a double prodrug modified with 5'-ProTide and N 4-propionyl ester, exhibiting anti-SARS-CoV-2 activity (EC50 = 3.22 μM). Anti-SARS-CoV-2 agent prodrug-1 is rapidly converted by esterases into intermediate 4, which has stronger plasma metabolic stability and can be rapidly activated to exert antiviral effects. Anti-SARS-CoV-2 agent prodrug-1 shows anti-SARS-CoV-2 activity in vitro and exhibits low cytotoxicity. Anti-SARS-CoV-2 agent prodrug-1 can be used in studies related to SARS-CoV-2 infection .
loading...
    loading...
Cat. No.: HY-189242
CAS No.: 3133817-84-9
Research Areas:  

Cancer

PARP1/PRMT5-IN-1 is an inhibitor of PARP1 and PRMT5, with an IC50 of 0.60 nM against PARP1 and an IC50 of 4.67 nM against PRMT5. PARP1/PRMT5-IN-1 downregulates the homologous recombination (HR)-associated factors BRCA1, BRCA2, and RAD51, thereby suppressing homologous recombination function. PARP1/PRMT5-IN-1 induces the accumulation of DNA double-strand breaks. PARP1/PRMT5-IN-1 triggers apoptosis. PARP1/PRMT5-IN-1 is applicable for breast cancer research .
loading...
    loading...
Cat. No.: HY-76705S
CAS No.: 2562378-12-3
Methyl N-methylanthranilate-d3 is the deuterated-labeled Methyl N-methylanthranilate (HY-76705). Methyl N-methylanthranilate is an N-alkylated anthranilate with a sweet citrus aroma, which is commonly used in perfume manufacturing. Methyl N-methylanthranilate is the dominant component in the defensive secretion of the millipede Typhloiulus orpheus. Methyl N-methylanthranilate exhibits quorum sensing inhibition and anti-biofilm activity against P. aeruginosa; it interferes with PQS synthesis via competitive inhibition of PqsA, but lacks bactericidal activity. Methyl N-methylanthranilate is sensitive to UVA/sunlight in human skin cells, and generates O2• - through type I photodynamic reactions, leading to lysosomal/mitochondrial damage, double-strand DNA breaks and apoptosis, with potential phototoxicity .
loading...
    loading...
Cat. No.: HY-P2307
CAS No.: 847829-41-8
Target:  

iGluR NO Synthase

Research Areas:  

Neurological Disease

Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
loading...
    loading...
Cat. No.: HY-P2307A
Target:  

iGluR NO Synthase

Research Areas:  

Neurological Disease

Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
loading...
    loading...
Cat. No.: HY-P3005
CAS No.: 9015-85-4
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

T4 DNA ligase is the product of gene 30 of phage T4. T4 DNA ligase catalyzes the repair of single-stranded nicks in duplex DNA and joins duplex DNA restriction fragments having either blunt or cohesive ends. T4 DNA ligase catalyze the sealing of adjacent 5′-phosphate and 3′-­hydroxyl termini at single-stranded breaks in double-stranded DNA.T4 DNA ligase is an ATP-dependent ligase enzyme. T4 DNA ligase can be used in various biotechnological applications. T4 DNA ligase can join the ends of single-stranded DNA in the absence of any duplex DNA structure at the ligation site .
loading...
    loading...
Cat. No.: HY-P5429
CAS No.: 146064-85-9
Target:  

Inhibitory Antibodies

Research Areas:  

Others

DNA-PK Substrate is a biological active peptide. (A substrate for DNA-dependent protein kinase (DNA-PK), phosphorylation. DNA-PK is essential for the repair of DNA double-strand breaks. This peptide corresponding to 11–24 amino acids of human p53 with threonine 18 and serine 20 changed to alanine is used as a substrate for the assay of DNA-PK activityPyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
loading...
    loading...
Cat. No.: HY-P992511

Target:  

PD-1/PD-L1 CTLA-4 VEGFR

Research Areas:  

Cancer

CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. CS2009 blocks the interactions of PD-1/PD-L1, CTLA-4/CD80 and VEGFA/VEGFR2, mediates checkpoint inhibition, and suppresses tumor angiogenesis. CS2009 reactivates PD-1/CTLA-4 double-positive tumor-infiltrating T lymphocytes, induces T cell activation, enhances tumor growth inhibition, promotes vascular normalization, improves T lymphocyte infiltration, and converts the immunosuppressive tumor microenvironment into an immunocompetent one. CS2009 can be used for the research of various advanced solid tumors .
loading...
    loading...
Cat. No.: HY-106055
CAS No.: 74817-61-1
Murabutide is an immunomodulator and also a NOD2 receptor agonist . Murabutide enhances the signal transduction of ATR and NOD2, mediates the activation of the DDR pathway, and thereby repairs radiation-induced DNA double-strand breaks. Murabutide inhibits radiation-induced cell apoptosis and protects cells and mice from radiation-induced toxic damage. Murabutide induces the expression and DNA-binding activity of Oct-1 in macrophages, thereby inhibiting the transcription and replication of HIV-1. Murabutide reduces the expression levels of CD4 and CCR5 on the surface of macrophages, and induces the secretion of β-chemokines, TNF-α and IL-6. Murabutide enhances non-specific viral resistance and targets reticuloendothelial cells. Murabutide can be used in research related to radiation-induced damage and human immunodeficiency virus type 1 infection .
loading...
    loading...
Cat. No.: HY-106289
CAS No.: 105026-50-4
Target:  

Antibiotic

Research Areas:  

Cancer

Antibiotic MX 2 is an orally active antibiotic that can cross the blood-brain barrier. Antibiotic MX 2 inhibits the growth of drug-sensitive and multidrug-resistant tumor cells, prolongs the survival of tumor-bearing mice, induces single-strand and double-strand DNA breaks, suppresses colony formation of fresh human-derived tumor cells, and overcomes multidrug resistance mediated by P-glycoprotein. Antibiotic MX 2 can be used in research related to L1210 leukemia, Lewis lung cancer, colon adenocarcinoma type 26 and type 38, gastric adenocarcinoma, non-small cell lung cancer, mammary adenocarcinoma, drug-resistant P388 leukemia, renal cancer, melanoma, ovarian cancer, breast cancer, small cell lung cancer, and colorectal cancer .
loading...
    loading...